Clinical Trial Update: Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection

View source ↗

Summary

This clinical trial update reports on the duration of protection provided by nirsevimab against hospitalization due to respiratory syncytial virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Nirsevimab (nirsevimab)

Snippet

Sponsor: Griffith University | Conditions: Respiratory Syncytial Viral (RSV) Infections | Status: ACTIVE_NOT_RECRUITING